Navigation Links
Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
Date:11/5/2013

Fort Myers, FL (PRWEB) November 05, 2013

A nearly decade long study documenting flu related fatalities in adolescents aged 18 and under uncovered a major gap in preventative care for children under the age of 6 months. According to the study published online in the October 28, 2013 Pediatrics Journal entitled, “Influenza-Associated Pediatric Deaths in the United States, 2004–2012”” by Karen K. Wong, MD, MPHa, Seema Jain, MDb, et al., 11% of documented children deaths were made up of infants under 6 months considered too young for preventative flu shots. Quoting the study, “Children without high-risk medical conditions were more likely to die before hospital admission (relative risk: 1.9; 95% confidence interval: 1.6–2.4) and within 3 days of symptom onset” Further the study states, “…these data which reveal that any child can be at risk of influenza associated death regardless of age or high risk medical conditions, support the recommendations that all children greater or equal to 6 months of age receive annual influenza vaccinations.”

The study fails to offer advice on alternative flu treatments for infants under the age of 6 months. The study did recommend individuals close to the infant receive flu vaccinations. With likely exposure to extended family members, friends, public areas, and daycare centers, the recommendation would be hard to follow.

According to the CDC, “For the 2013-2014 influenza season, trivalent and quadrivalent inactivated influenza vaccine (IIV) is available…IIV should not be administered to infants less than 6 months of age.” Additionally, according to the CDC, “A two-year study of children aged 6–24 months found that the vaccine was 66% effective in preventing laboratory-confirmed influenza in one year of the study (Hoberman et al., 2003). "

Kevin McGuire, President of UV Technologies, LLC and inventor of patent pending UV-Aid, states, “Flu vaccines are not 100% effective in stopping the flu and additionally vaccinations are NOT recommended for children under the age of 6 months. This leaves gap in flu protection especially for infants under the age of 6 months. Photo-oxidation provides a natural and effective option for preventing airborne diseases like the flu."

CDC data shows that during the summer seasons when photo-oxidation is highest, the occurrence of flu is 100 times less than during the winter. Further, the American Academy of Pediatrics recommends exclusive breastfeeding for the first 6 months and continued breastfeeding for at least the first year as foods are introduced.

About UV Technology, LLC:
UV Technologies, LLC’s mission is to promote health and well-being through innovative light based technologies. UV-Aid helps prevent colds, flu, sore throats, sinus and ear infections through the process of photo-oxidation. Hydrogen peroxide is produced in areas susceptible to infection. UV Technologies offers other innovative products for its customers to live a healthier and more productive life including iTanSmart, an app. that helps prevent sunburns and manage sun exposure.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11294801.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds ... the launch of a new DRTV campaign with Belly Bands. , Having a dog ... from sprays to puppy pads and find nothing works, get Belly Bands, the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology: